Thomas Andrew Davis - Net Worth and Insider Trading
Thomas Andrew Davis Net Worth
The estimated net worth of Thomas Andrew Davis is at least $3,101 dollars as of 2024-09-20. Thomas Andrew Davis is the Sr. VP & CMO of Celldex Therapeutics Inc and owns about 67 shares of Celldex Therapeutics Inc (CLDX) stock worth over $2,734. Thomas Andrew Davis is the Chief Medical Officer of Genvec Inc and owns about 50 shares of Genvec Inc (GNVC) stock worth over $360. Thomas Andrew Davis is also the CHIEF MEDICAL OFFICER of Genocea Biosciences Inc and owns about 68,330 shares of Genocea Biosciences Inc (GNCAQ) stock worth over $7. Details can be seen in Thomas Andrew Davis's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas Andrew Davis has not made any transactions after 2022-04-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Thomas Andrew Davis
Thomas Andrew Davis Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas Andrew Davis owns 4 companies in total, including Genocea Biosciences Inc (GNCAQ) , Celldex Therapeutics Inc (CLDX) , and Genvec Inc (GNVC) among others .
Click here to see the complete history of Thomas Andrew Davis’s form 4 insider trades.
Insider Ownership Summary of Thomas Andrew Davis
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| GNCAQ | Genocea Biosciences Inc | 2022-04-04 | CHIEF MEDICAL OFFICER |
| CLDX | Celldex Therapeutics Inc | 2010-09-16 | Sen. VP & Ch. Medical Officer |
| GNVC | Genvec Inc | 2006-01-18 | Chief Medical Officer |
 | | 2018-10-01 | CHIEF MEDICAL OFFICER |
Thomas Andrew Davis Latest Holdings Summary
Thomas Andrew Davis currently owns a total of 3 stocks. Among these stocks, Thomas Andrew Davis owns 67 shares of Celldex Therapeutics Inc (CLDX) as of September 16, 2010, with a value of $2,734 and a weighting of 88.18%. Thomas Andrew Davis owns 50 shares of Genvec Inc (GNVC) as of November 22, 2005, with a value of $360 and a weighting of 11.6%. Thomas Andrew Davis also owns 68,330 shares of Genocea Biosciences Inc (GNCAQ) as of April 4, 2022, with a value of $7 and a weighting of 0.22%.
Latest Holdings of Thomas Andrew Davis
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CLDX | Celldex Therapeutics Inc | 2010-09-16 | 67 | 40.81 | 2,734 |
| GNVC | Genvec Inc | 2005-11-22 | 50 | 7.19 | 360 |
| GNCAQ | Genocea Biosciences Inc | 2022-04-04 | 68,330 | 0.00 | 7 |
Holding Weightings of Thomas Andrew Davis
Thomas Andrew Davis Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas Andrew Davis has made a total of 0 transactions in Celldex Therapeutics Inc (CLDX) over the past 5 years. The most-recent trade in Celldex Therapeutics Inc is the acquisition of 167 shares on September 16, 2010, which cost Thomas Andrew Davis around $9,425.
According to the SEC Form 4 filings, Thomas Andrew Davis has made a total of 0 transactions in Genvec Inc (GNVC) over the past 5 years. The most-recent trade in Genvec Inc is the acquisition of 50 shares on November 22, 2005, which cost Thomas Andrew Davis around $9,100.
According to the SEC Form 4 filings, Thomas Andrew Davis has made a total of 1 transactions in Genocea Biosciences Inc (GNCAQ) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Genocea Biosciences Inc is the sale of 1,091 shares on April 4, 2022, which brought Thomas Andrew Davis around $1,364.
Insider Trading History of Thomas Andrew Davis
- 1
Thomas Andrew Davis Trading Performance
GuruFocus tracks the stock performance after each of Thomas Andrew Davis's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas Andrew Davis is 16.24%. GuruFocus also compares Thomas Andrew Davis's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas Andrew Davis within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Thomas Andrew Davis's insider trading performs compared to the benchmark.
Performance of Thomas Andrew Davis
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 8.73 | | | | | |
| Relative Return to S&P 500(%) | 6.16 | | | | | |
Thomas Andrew Davis Ownership Network
Thomas Andrew Davis Owned Company Details
What does Genocea Biosciences Inc do?
Who are the key executives at Genocea Biosciences Inc?
Thomas Andrew Davis is the CHIEF MEDICAL OFFICER of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , director & President and CEO William D Clark , and CHIEF FINANCIAL OFFICER Diantha Duvall .
Genocea Biosciences Inc (GNCAQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GNCAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GNCAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Genocea Biosciences Inc (GNCAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Genocea Biosciences Inc Insider Transactions
Thomas Andrew Davis Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas Andrew Davis. You might contact Thomas Andrew Davis via mailing address: 65 West Watkins Mill Road, Gaithersburg Md 20878.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
